APPROVED_FOR_MARKETING

239 clinical trials · Status

Record	Firm	Date
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) (NCT04323761)	Gilead Sciences
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) (NCT06360237)	Ionis Pharmaceuticals, Inc.
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options (NCT00042393)	Gilead Sciences
Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment (NCT00683306)	AstraZeneca
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination (NCT01432301)	Wellstat Therapeutics
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury (NCT01412359)	Jeffrey Rudolph
Expanded Access to Glecaprevir/ Pibrentasvir (NCT03123965)	AbbVie
Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer (NCT03025867)	Tesaro, Inc.
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) (NCT00377065)	Merck Sharp & Dohme LLC
Axicabtagene Ciloleucel Expanded Access Study (NCT03153462)	Kite, A Gilead Company
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (NCT04162756)	Kite, A Gilead Company
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) (NCT03829579)	Janssen Research & Development, LLC
Humanitarian Device Exemption (NCT00580658)	Vanderbilt University Medical Center
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs (NCT00354627)	Tibotec Pharmaceuticals, Ireland
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS (NCT05286372)	Amylyx Pharmaceuticals Inc.
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options (NCT03825484)	Janssen Scientific Affairs, LLC
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors (NCT03154437)	Genentech, Inc.
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation (NCT03245424)	Agios Pharmaceuticals, Inc.
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL (NCT04300803)	MorphoSys AG
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST (NCT04148092)	Deciphera Pharmaceuticals, LLC
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia (NCT02136511)	Gilead Sciences

Track APPROVED_FOR_MARKETING automatically

Every clearance here is in the API, with alerts when new ones post.